PaulDenisLegerMD

PubMed

• A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials.
  Paul Leger, Stanley Frencher Jr, Jones T Nauseef, Brian Jones, Mehmet A Bilen
  Future Oncology. 2025-04-01
• Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate...
  Kelly Gaudian, Min Jung Koh, Min Ji Koh, Ryan R Collins, Shaine Eden
  Frontiers in Oncology. 2025-01-01
• Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
  Sarthak Shah, Abigail Pepin, Simran Jatar, Jessica Hsueh, Lindsey Gallagher
  Cureus. 2024-03-01

Journal Articles

• Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation  
  1) Leger P., Chirva S., Nwogu J., Tuner M., Richardson D., Baker P., Leonard M., Erdem H., Olson L., Haas D., Pharmacogent Genomics, 1/28/2018
• A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.  
  2) Nakajima E., Leger P., Mayer I., Neuss M., Chism D., Rathmell K, Kidney Cancer, 7/2017
• Clinical features of acquired resistance in anti-PD-1 therapy  
  3) Wang D., Zeynep E., Ozgun A., Leger P., Zhao S., Ye F., Luke J., Joseph R., Sosman J., Johnson D., Buchbinder E, Cancer Immunology Research, 5/2017
• Pharmacogenetics of Efavirenz Discontinuation for Reported Central Nervous System Symptoms Appears to Differ by Race  
  4) Leger P., Chirwa S., Turner M., Richardson D., Baker P., Leonard M., Erdem H., Olson L., Haas D.., Pharmacogenetics and Genomics, 10/2016
• Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multi-country open-label randomi...  
  1) Hosseinipour M., Bisson G., Miyahara S. Leger P., Gupta A., The Lancet, 3/2016
• Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa  
  5) Sinxadi P., Leger P., McIleron H., Smith P., Dave J., Levitt N., Maartens G., Haas D.., Br J Clin Pharmacol, 7/2015
• Multiple Genetic Variants Predict Steady-State Nevirapine Clearance in HIV-infected Cambodians  
  7) Bertrand J., Chou M., Richardson D., Verstuyft C., Leger P., Mentre F., Taburet A., Haas D., Pharmacogenet Genomics., 12/2012
• Virologic, Clinical and Immunologic Responses following Failure of First-line Antiretroviral Therapy in Haiti  
  2) Charles M., Leger P., Severe P., Guiteau C., Apollon A., Gulick R., Johnson W., Pape J., Fitzgerald D, Journal of the International AIDS Society, 6/2012
• 5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti  
  6) Leger P., Charles M., Severe P., Riviere C., Pape J., Fitzgerald D, New England Journal of Medicine, 8/2009
• Antiretroviral Therapy in a Thousand Patients with AIDS in Haiti  
  12) Severe P., Leger P.,Charles M., Noel F., Bonhomme J., Bois G.,George E., Kenel-Pierre S.,Wright P., Gulick R., Johnson W., Pape J.,Fitzgerald D, New England Journal of Medicine, 12/2005
• Join now to see all